Enhertu Success Stories: Verified Outcomes, Clinical Evidence, and Patient Impact
breast-cancer
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate that targets HER2 and delivers a topoisomerase inhibitor payload. It is approved for HER2-positive breast cancer a...
Open article